ArticleOncoimmunology
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.BMC cancer · 2018Trial
- Article
- Non-clinical safety considerations on genome editing using the CRISPR/Cas system.Genes & diseases · 2026Review
- Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.European journal of cancer (Oxford, England : 1990) · 2023Review
- NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.American journal of translational research · 2022Article
- Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.Frontiers in oncology · 2022Article
- Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.Cells · 2021Review
- Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.Frontiers in immunology · 2021Review
- Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application.Frontiers in oncology · 2021Review
- Review
- Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Metastatic Burden Defines Clinically and Biologically Distinct Subgroups of Stage 4 High-Risk Neuroblastoma.Journal of clinical medicine · 2020Article
- Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.Journal of translational medicine · 2020Review
- Review
- Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.Seminars in immunology · 2020Review
- CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.Frontiers in immunology · 2019Review
- Adoptive Cell Therapy in Treating Pediatric Solid Tumors.Current oncology reports · 2018Review
- Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma.Journal of immunology research · 2018Review
- Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.Oncotarget · 2017Article
- Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.Cytotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer-testis antigen NY-ESO-1 is expressed by many solid tumors and has limited expression by mature somatic tissues, making it a highly attractive target for tumor immunotherapy. Targeting NY-ESO-1 using engineered T cells has demonstrated clinical efficacy in the treatment of some adult tumors. Neuroblastoma is a significant cause of cancer mortality in children, and is a tumor type shown to be responsive to immunotherapies. We evaluated a large panel of primarily resected neuroblastoma samples and demonstrated that 23% express NY-ESO-1. After confirming antigen-specific activity of T cells genetically engineered to express an NY-ESO-1 directed high-affinity transgenic T cell receptor
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.